| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | CYTK Cytokinetics, Incorporated | Kaye Edward M. Md46 | Director | Sell | 2,933 | $76.09 | $223,171.97 | -22.2% | - | - | |
| Jun 1, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | Sell | 1,042 | $495.74 | $516,561.08 | -9.4% | - | - | |
| Jun 1, 2026 | MAIA Maia Biotechnology, Inc. | Gryaznov Sergei | Chief Scientific Officer | Buy | 2,000 | $1.35 | $2,690.00 | +4.5% | - | - | |
| Jun 1, 2026 | MAIA Maia Biotechnology, Inc. | Vitoc Vlad | Chief Executive Officer | Buy | 72,700 | $1.39 | $100,885.79 | +8.0% | - | - | |
| Jun 1, 2026 | SNSE Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% Owner | Sell | 25,000 | $20.02 | $500,542.64 | -8.7% | - | - | |
| Jun 1, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Horn Howard81 | Chief Financial Officer | Sell | 4,653 | $23.77 | $110,601.81 | -4.2% | - | - | |
| Jun 1, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher45 | Chief Executive Officer | Sell | 30,000 | $95.84 | $2,875,103.34 | -2.4% | - | - | |
| Jun 1, 2026 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S.68 | Chief Scientific Officer | Sell | 4,170 | $13.16 | $54,862.19 | -2.9% | - | - | |
| Jun 1, 2026 | GILD Gilead Sciences, Inc. | O'Day Daniel Patrick | Chairman &CEO | Sell | 15,000 | $131.46 | $1,971,846.67 | -0.8% | - | - | |
| Jun 1, 2026 | SNSE Sensei Biotherapeutics, Inc. | Peyer James | 10% Owner, See Remarks Below | Sell | 25,000 | $20.02 | $500,542.64 | -8.7% | - | - | |
| Jun 1, 2026 | FDMT 4d Molecular Therapeutics, Inc. | Kirn David78 | See Remarks | Sell | 1,922 | $10.02 | $19,257.86 | -0.2% | - | - | |
| Jun 1, 2026 | CYTK Cytokinetics, Incorporated | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1,111,200.00 | -20.4% | - | - | |
| Jun 1, 2026 | MDWD Mediwound Ltd. | Fox David Morton | Director | Buy | 3,537 | $14.11 | $49,900.57 | +5.9% | - | - | |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L74 | Chief Financial Officer | Sell | 7,500 | $71.06 | $532,936.98 | -2.4% | - | - | |
| Jun 1, 2026 | SNDX Syndax Pharmaceuticals, Inc. | Goldan Keith A.53 | Chief Financial Officer | Sell | 1,177 | $18.99 | $22,351.23 | -0.8% | - | - | |
| Jun 1, 2026 | GNLX Genelux Corporation | Thomas John77 | Director | Sell | 10,000 | $2.98 | $29,801.00 | -2.1% | - | - | |
| Jun 1, 2026 | OBIO Orchestra Biomed Holdings, Inc. | Hochman David P | See Remarks | Buy | 5,000 | $3.83 | $19,150.00 | +0.5% | - | - | |
| Jun 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Raykov Rosty54 | Director | Sell | 9,747 | $9.62 | $93,766.14 | -7.0% | - | - | |
| Jun 1, 2026 | NBP Novabridge Biosciences | Xu Cong Claire | SVP, Clinical Development | Sell | 3,494 | $3.94 | $13,766.36 | -1.2% | - | - | |
| Jun 1, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Ramasastry Saira54 | Director | Sell | 3,977 | $100.00 | $397,700.00 | -100% | - | - | |
| Jun 1, 2026 | CORT Corcept Therapeutics Incorporated | Belanoff Joseph K77 | Chief Executive Officer | Sell | 12,837 | $69.74 | $895,252.38 | -0.5% | - | - | |
| Jun 1, 2026 | ILMN Illumina, Inc. | Meister Keith A.61 | Director | Sell | 669,596 | $159.86 | $107,042,630.86 | -1.2% | - | - | |
| May 29, 2026 | ANTX An2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | Sell | 265 | $4.43 | $1,173.95 | -0.4% | - | - | |
| May 29, 2026 | MAZE Maze Therapeutics, Inc. | Dandekar Atul | Csbo | Sell | 7,500 | $26.34 | $197,553.75 | -23.2% | - | - | |
| May 29, 2026 | ILMN Illumina, Inc. | Davies Scott M | Chief Legal Officer | Sell | 615 | $160.00 | $98,400.00 | -2.8% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.